video
Video: PHERAstar FSX Customer testimonial
In this video, Becky Allsopp from Sygnature Discovery talks about Drug Discovery Research and how she uses the Microplate Reader PHERAstar FSX for their research.
List view / Grid view
Drug Discovery Processes
whitepaper
Tech note: Fast, simple, homogeneous assays for characterisation of Fc receptor binding using AlphaLISA
AlphaLISA® provides a robust assay that facilitates the design and development of antibody therapeutics.
whitepaper
Whitepaper: Opportunities in preclinical development
This whitepaper explains how you can find ways to optimise the holistic preclinical development process...
article
Genomics in drug development and safety testing; from target identification to genomic toxicology
In the annual report of the Chief Medical Officer, 1 Dame Sally Davies has declared that we are part of ‘generation genome’ – the era in which we reap the rewards of our advances in genomic technologies and improvements in our understanding of the whole genome in human health.
news
Progress toward improved Wilson’s disease drug
Researchers have conducted promising preclinical experiments on a compound that could be used to treat Wilson's disease...
news
Researchers reveal therapeutic target for Influenza A
Researchers show altering the molecular interactions between the flu virus and host genes stunts virus replication...
news
Mini-ecosystems developed to test a molecules therapeutic effect
Research scientists have solved a major problem in chemistry and drug development by using droplet-sized 'mini-ecosystems to quickly see if a molecule can function as a potential therapeutic...
news
Platypus venom inspires potential new diabetes treatments
A metabolic hormone found in the venom and gut of Australia’s iconic platypus will now be investigated for its potential to treat type 2 diabetes...
product
Mouse IgG type and Titer Kit
15 June 2018 | By IntelliCyt
The Intellicyt Mouse IgG Type and Titer Kit is a high throughput, multiplexed assay kit that enables analyses of isotype, titer and cell health in a single assay...
whitepaper
Application note: A novel way to expedite antibody discovery
Analyse isotype titer and cell health in one assay...
article
Streamlining drug discovery assays for cancer and cardiovascular disease
For lead optimisation, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological relevance is driving ongoing growth in cell-based assays.
article
Expert view: Rising growth of the global high‑content screening software and services market
The global high-content screening (HCS) software and services market accounted for over $500 million in 2017 and is expected to reach approximately $1.4 billion by 2026, increasing at a compound annual growth rate of more than 11%, says Jeff McMillan, Senior Product Manager Imaging, Molecular Devices.
article
Transforming translational research: CANscriptTM – a better predictive model for oncology
This webinar focused on a recent study evaluating a cohort of head and neck squamous cell carcinoma (HNSCC) patient tumours treated with anti-PD1 using CANscript™.
article
Automated assessment of liver and cardiac toxicities in lead optimisation
This webinar, supported by Tecan, focused on the automated assessment of liver and cardiac toxicities in lead optimisation, using biochemical and human iPS cell assays.
article
Expert view: Overcoming the problems of working with human primary hepatocytes
Human primary hepatocytes (hpheps) are the gold standard for in vitro evaluation of drug metabolism, drug-drug interactions, and metabolic disease research. However, hpheps don’t survive in standard 2D culture for very long – no longer than two or three days.
